4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations

California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series ... Read More